Biotech Values

[genisi]

amyloid research will continue in earlier disease

This should give further push to biomarkers testing and use in AD as I doubt that current gold standard for cognitive and functional measurement are sensitive enough to detect changes between treated and placebo early patients in order to determine the efficacy of a drug. That is why I was interested in the ADNI data (#msg-37700576 , #msg-53164021 , #msg-64638427 ).